- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2018 (FDA) and 2018 (EMA).
- Why 3/10
- No hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for Delstrigo in the next ~12 months. The drug is already approved and marketed. The recent FDA sNDA approval (October 1, 2026) and European Commission authorization update are already completed events. ImpactScore is 3 because Delstrigo is a small product within Merck's massive diversified portfolio.
Delstrigo is a mature, marketed product with no upcoming binary catalyst. The recent FDA sNDA approval (October 1, 2026) and European Commission authorization update (October 2026) are already priced in. Watch for quarterly sales trends and any generic entry developments as patents approach expiry in the mid-2030s, but this drug alone will not drive MRK's share price.
Price Chart
Executive Summary
DELSTRIGO is Merck's once-daily, fixed-dose combination tablet (doravirine/lamivudine/tenofovir disoproxil fumarate) for HIV-1 infection, originally FDA-approved in August 2018 and also authorized in the EU. It is a complete single-tablet regimen in the NNRTI class, competing primarily against Gilead's Biktarvy and other integrase-inhibitor-based regimens. Delstrigo generated approximately $75 million in Q1 2026 sales (up ~12% YoY), representing a small fraction of Merck's $65B+ annual revenue. The FDA approved a supplemental NDA in October 2026, and the European Commission updated its marketing authorization in the same month. With no upcoming binary catalysts and patent protection extending to the mid-2030s, Delstrigo is a steady but minor contributor to Merck's diversified portfolio.
How It Works
Delstrigo is a once-daily single tablet that combines three antiviral drugs: doravirine (a non-nucleoside reverse transcriptase inhibitor, or NNRTI), lamivudine (a nucleoside reverse transcriptase inhibitor, or NRTI), and tenofovir disoproxil fumarate (another NRTI). Together, these drugs block the HIV virus from replicating by interfering with the reverse transcriptase enzyme the virus needs to multiply. It is a complete regimen, meaning patients take one pill once a day with no other HIV medications needed.
Trial Status
Delstrigo was approved by the FDA on August 30, 2018, based on Phase 3 trials (DRIVE-AHEAD, DRIVE-FORWARD) in treatment-naive adults. A supplemental approval in 2022 expanded the label to include virologically suppressed patients switching therapy (DRIVE-SHIFT trial) and pediatric patients weighing at least 35 kg. The most recent FDA supplement (sNDA S-019) was approved on/about October 1, 2026. The drug is commercially available in the US and EU.
The Two-Sided Case
Upcoming Catalysts
- No hard binary catalysts scheduled. Quarterly sales reports are the main ongoing event to track commercial trajectory.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Merck & Co., Inc. 8-K MRK ·Originating report